We are seeking partners to license our under-developing products or to grant the right of using our platform delivery technologies for US, Europe and Japan markets. Since the above-mentioned advanced dosage forms, sustained-release microspheres for native proteins and phase-transition microneedle patch for efficient and accurate transdermal delivery, are the only available systems in their respective categories, we may offer our partners with veritably exclusive right of determined products and markets.
|
|
